FATE

Fate Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website fatetherapeutics.com
Employees(FY) 551
ISIN US31189P1021

Performance

-6.72%

-31.27%

-38.84%

-43.08%

-40.64%

YTD

-14.62%

Profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Advanced Technical Analysis

Technical Analysis of FATE 2024-11-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 43 suggesting a neutral stance, and a Technical Score of 26 reinforcing the bearish outlook. This combination points to a challenging environment for the stock, with potential for further declines.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of FATE

Stock Rank

Recent News & Updates

2024-11-17 19:05
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence(Globenewswire)
2024-11-17 19:00
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence(Globenewswire)
2024-11-12 04:20
Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates(Yahoo Finance)
2024-11-12 03:18
Fate Therapeutics: Q3 Earnings Snapshot(Yahoo Finance)
2024-11-12 03:01
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates(Globenewswire)
2024-11-09 00:30
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting(Globenewswire)
2024-11-08 03:01
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting(Globenewswire)
2024-11-04 03:01
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-10-02 04:01
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-09-12 16:01
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference(GlobeNewswire)
2024-09-12 04:01
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference(Globenewswire)
2024-09-11 23:30
Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report?(Yahoo Finance)
2024-08-22 07:04
Broker Revenue Forecasts For Fate Therapeutics, Inc. (NASDAQ:FATE) Are Surging Higher(Simply Wall St.)
2024-08-16 00:00
All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy(Yahoo Finance)
2024-08-15 06:31
Fate Therapeutics Second Quarter 2024 Earnings: Beats Expectations(Simply Wall St.)
2024-08-14 10:07
FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow(Zacks)
2024-08-13 17:06
Fate Therapeutics Q2 Loss Narrows, Revenue Rises(MT Newswires)
2024-08-13 16:05
Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates(GlobeNewswire)
2024-08-13 05:25
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates(Yahoo Finance)
2024-08-13 04:25
Fate Therapeutics: Q2 Earnings Snapshot(Yahoo Finance)
2024-08-13 04:05
Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates(Globenewswire)
2024-08-02 16:01
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)(GlobeNewswire)
2024-08-02 04:01
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-07-31 08:52
Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?(Simply Wall St.)
2024-07-31 08:00
Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors(GlobeNewswire)
2024-07-30 20:00
Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors(Globenewswire)
2024-07-21 05:37
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?(Motley Fool)
2024-07-02 16:01
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)(GlobeNewswire)
2024-07-02 04:01
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-06-17 07:04
Piper Sandler Upgrades Fate Therapeutics to Overweight From Neutral, Adjusts Price Target to $6 From $4(MT Newswires)

Page 1 of 7

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.